The case for & against
Bull & Bear analysis
Bearish
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biopharmaceutical company specializing in the development of innovative pain management therapies that leverage proprietary technology aimed at reducing the abuse potential of opioids. The company's flagship product, PF614, utilizes the TAP (Trypsin Activated Protection) and MPAR (Multi-Pill Abuse Resistance) platforms, positioning itself within the urgent context of the ongoing opioid crisis as it aims to provide safer alternatives to conventional opioids.
Bull says
- ↑FDA granted PF614 Breakthrough Therapy designation, speeding review.
- ↑Bioequivalence trials show PF614 matches OxyContin efficacy, safer profile.
- ↑Secured $4.6M in federal grants, plus $2.8M pending in July.
- ↑Phase III trials slated for late 2024 amid strong demand.
- ↑High growth factor and robust liquidity indicate upward momentum.
- ↑Innovative TAP and MPAR platforms position PF614 favorably vs peers.
Bear says
- ↓Ended Q4 2023 with $1.1M cash, needing funds pre-Phase III.
- ↓Net loss of $3.5M in Q4 vs $5.5M a year earlier.
- ↓Profitability score weak and earnings yield negative, undercutting finances.
- ↓R&D spend may exceed $5M in Phase III, boosting cash burn.
- ↓Momentum factor is negative, reflecting recent weak share performance.
- ↓Market wariness of opioids could delay PF614 adoption.
Earnings Call · Q1 2022 · Mgmt. Guidance
Updated 06-28-2026neutral
Transcript signals
Bull points
- we ended the first quarter of 2022 with $8.4 million in cash and cash equivalents. Cash used in operating activities for the first quarter of 2022 totaled $3.4 million, resulting from the clinical advancement of our product candidates and increased costs related to operating as a public company. In addition to our cash balance, remaining funding from approved federal grants totaled $4.1 million at the end of the first quarter.
- On July 1st, we also expect to be formally awarded the fourth year of grant funding for the MPAR program for $2.8 million. These funds would help support the continued clinical development of PS614 MPAR.
Bear points
- Overall, our net loss for the first quarter of 2022 totaled $1 million compared to a net loss of $0.9 million for the comparable year-ago period. As we are a clinical stage biotech company, development of our product candidates is expected to continue, resulting in expected losses for the foreseeable future.
- we estimate that our cash burn will be approximately $4 million on a quarterly basis. Our plans reflect that our estimated runway of current cash resources takes us into the fourth quarter of this year.
Read full transcript analysis ›